Among them, 40 (3%) patients had a second episode of G3-4 neutropenia though receiving G-CSF as secondary prophylaxis, 32 (6%) and 8 (1%) in the FOLFOXIRI/bevacizumab and doublets/bevacizumab group, respectively (P = 0.30). The gene discussed is CSF3; the disease is neutropenia.